Table 1. Clinical Characteristics of the Patients (n=244).
| CBCS (n=117) | SIBCS (n=127) | p value | ||
|---|---|---|---|---|
| Age (yr) | 55.90±10.10 | 53.10±11.00 | 0.065 | |
| BMI (kg/m2) | 23.62±3.03 | 23.35±3.54 | 0.523 | |
| Pathologic type | 0.284 | |||
| IDC | 96 (82.10) | 111 (87.40) | ||
| DCIS | 21 (18.00) | 5 (3.90) | ||
| Other | 14 (12.00) | 11 (8.70) | ||
| Histologic grade | 0.144 | |||
| 1 | 33 (28.20) | 31 (24.40) | ||
| 2 | 43 (36.80) | 63 (49.60) | ||
| 3 | 32 (27.40) | 29 (22.80) | ||
| Unknown | 9 (7.70) | 4 (3.10) | ||
| Pathologic T stage | 0.242 | |||
| ≤T1 | 107 (91.50) | 115 (90.50) | ||
| T1> | 10 (8.50) | 12 (9.40) | ||
| Tumor size (mm) | 12.10±7.80 | 11.00±7.70 | 0.274 | |
| Distance from nipple (cm) | 4.00±3.00 | 4.00±3.00 | 0.840 | |
| Nodal status | 0.022 | |||
| Node negative | 106 (90.60) | 103 (81.10) | ||
| Node positive | 11 (9.40) | 24 (18.10) | ||
| Number of lymph nodes retrieved | 0.931 | |||
| ≤5 | 99 (84.60) | 104 (81.80) | ||
| 5>and<11 | 12 (10.20) | 21 (16.50) | ||
| 11≥ | 6 (5.10) | 2 (1.50) | ||
| ER | 0.479 | |||
| Negative | 32 (27.40) | 40 (31.50) | ||
| Positive | 85 (72.60) | 87 (68.50) | ||
| PR | 0.172 | |||
| Negative | 46 (39.30) | 61 (48.00) | ||
| Positive | 71 (60.70) | 66 (52.00) | ||
| Her2 | 0.648 | |||
| No overexpression | 96 (82.10) | 107 (84.30) | ||
| Overexpression | 21 (17.90) | 20 (15.70) | ||
| Ki-67 | 0.218 | |||
| <14 | 49 (41.90) | 51 (40.20) | ||
| ≥14 | 68 (58.10) | 74 (58.30) | ||
| Unknown | 0 (0) | 2 (1.60) | ||
| Neoadjuvant therapy | 0.009 | |||
| Not done | 105 (89.70) | 98 (77.20) | ||
| Done | 12 (10.30) | 29 (22.80) | ||
| ASA score | 0.999 | |||
| <2 | 95 (81.90) | 104 (81.90) | ||
| ≥2 | 21 (18.10) | 23 (18.10) | ||
ASA, American Society of Anesthesiology; BMI, body mass index; CBCS, conventional breast-conserving surgery; DCIS, ductal carcinoma in situ; ER, estrogen receptor; IDC, invasive ductal carcinoma; PR, progesterone receptor; SIBCS, single-incision breast-conserving surgery.
Data are expressed as n (%) or mean±SD.